News & Events

Otonomy to Present AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference

SAN DIEGO, April 21, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that previously reported results from two Phase 3 trials evaluating AuriPro™ in pediatric patients with middle ear effusion undergoing tympanostomy tube placement surgery will be presented in a podium presentation at the 2015 American Society of Pediatric Otolaryngology...

read more

Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere’s Disease Patients

SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has achieved target enrollment in its multiple-dose safety study of OTO-104 in patients with Ménière’s disease. This prospective, randomized, placebo-controlled study, designed to evaluate the safety of quarterly dosing of OTO-104, enrolled a total of 128...

read more

Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Label Expansion Indication

AuriPro to be Evaluated in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the enrollment of the first patients in a Phase 2 clinical trial evaluating AuriProTM for the treatment of pediatric patients with acute otitis media with tympanostomy tubes (AOMT). A...

read more

ZS Pharma Announces Upsizing and Pricing of $186 Million Public Offering of Common Stock

REDWOOD CITY, Calif., March 25, 2015 (GLOBE NEWSWIRE) — ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced the upsizing and pricing of its underwritten public offering. The size of the offering has been increased from the previously announced 3,300,000 shares of common stock to 4,015,939 shares of common stock. The shares are being offered to the public at a price...

read more

ZS Pharma Announces Proposed Public Offering of Common Stock

Redwood City, Calif. – March 23, 2015 – ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it intends to offer and sell, subject to market and other conditions 3,300,000 shares of its common stock in an underwritten public offering. A single selling stockholder, Alta Partners VIII, L.P., expects to grant the underwriters a 30-day option to purchase up to...

read more

Lyric Pharmaceuticals Announces $20.4M Series A Funding Round

SOUTH SAN FRANCISCO, CA, February 26, 2015 – Lyric Pharmaceuticals Inc. today announced the initial closing of a Series A financing round totaling $20.4 million. The financing, co-led by RiverVest Venture Partners, Santé Ventures and Third Point Ventures, includes participation by Aperture Venture Partners. Lyric is a clinical-stage pharmaceutical company co-founded in 2013 by David Wurtman, M.D., M.B.A., President & Chief Executive Officer and M. Scott Harris, M.D., Chief Medical Officer. In 2014, Lyric closed a seed financing...

read more

Otonomy Submits New Drug Application to the FDA for AuriPro(TM)

SAN DIEGO, Feb. 26, 2015 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of AuriProTM as a treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery. The NDA submission is supported by data...

read more

Neuros Medical Enrolls First Patients in Pivotal Study for Post-Amputation Pain

Cleveland, OH, January 28, 2015– Neuros Medical, Inc., a medical device company, announced it has enrolled the first patients in its pivotal clinical trial to evaluate the Company’s patented Altius® System High Frequency Nerve Block technology for the management of intractable limb pain of amputees. The prospective, randomized, controlled pivotal clinical trial will consist of up to 130 patients at 15 institutions to evaluate the safety and efficacy of Neuros Medical’s Altius System. When completed, the results will support a PreMarket...

read more

Big year: RiverVest turns in strong 2014, eyes 2015 growth

By:  Brian Feldt, Reporter St. Louis Business Journal December 26, 2014   RiverVest Venture Partners, the Clayton-based venture capital firm, has for several years been considered one of the leading investing firms in the nation when it comes to medical technology. This year may be its best campaign yet. RiverVest exited a dozen portfolio companies since 2011, returning $290.5 million to the firm, or 3.5 times the dollars invested in those companies ($83 million).  Read more. Source: St. Louis Business...

read more

Otonomy Provides Corporate and Product Pipeline Update

SAN DIEGO, Jan. 8, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced an update on its corporate activities and product pipeline.   Corporate and Product Pipeline Update • NDA Submission for AuriPro™ planned for 1Q2015: Preparation of the New Drug Application (NDA) for AuriPro is in process, and incorporates feedback received from a...

read more